News

H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The ...
H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $32 from $29 and keeps a Buy rating on the shares. The firm says the ...
H.C. Wainwright analyst Amit Dayal lowered the firm’s price target on ClearSign (CLIR) to $2 from $6 and keeps a Buy rating on the shares. The ...
The Glynn Academy baseball team faced off against Greenbrier in the Region 1-5A tournament semifinals on Tuesday with a berth in the region championship game on the line.
Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $17.08, a high estimate of ...
Analysts have recently evaluated Verve Therapeutics and provided 12-month price targets. The average target is $17.5, ...
The gross proceeds from the, before deducting the placement agent’s fees and other offering expenses payable by the Company, are expected to be $3.0 million. Can-Fite intends to use the net proceeds ...